Jan 23, 2023 | Press Release
Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular cancer patients Data reinforce the potential of Xerna TME Panel to substantially improve outcomes for patients Waltham MA, January 23, 2023,...
Sep 12, 2022 | Press Release
Better 24-month survival was achieved when durvalumab was used for maintenance compared to surveillance in esophagogastric adenocarcinoma patients with “high” Xerna TME Panel immune scores, despite these patients having a poorer prognosis Data suggest the Xerna TME...
Sep 8, 2022 | Press Release
Multicenter basket trial includes cohorts enrolling patients with colorectal and triple negative breast cancer Trial designed to assess efficacy, safety, and evaluate the relationship between tumor Xerna™ TME Panel biomarker subtype and treatment response Waltham, MA....
Jun 3, 2022 | Press Release
Trial’s 73% twelve-month overall survival rate in newly diagnosed glioblastoma patients compares favorably to historical benchmark of 60% Results show median progression-free survival of 6.9 months and median overall survival of 15.4 months Treatment led to...
Apr 21, 2022 | Press Release
Overall response rate (ORR) of 43% and median duration of response of 6 months seen with navicixizumab-paclitaxel combination in heavily pretreated platinum resistant ovarian cancer patients Xerna™ TME Panel shows enhanced response in biomarker positive (62%) vs....
Apr 11, 2022 | Press Release
AI-driven Xerna TME panel generates robust “binary-like” biomarker classifications that are prognostic across multiple tumor types Xerna TME Panel has potential to predict patient responses to angiogenic- and immune-targeted therapies Waltham, MA. April...